Expanded Access for ACE-011
- Conditions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Celgene
- Registration Number
- NCT03724227
- Locations
- 🇺🇸
Celgene, Summit, New Jersey, United States
Expanded Access for CC-2001
- Conditions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Celgene
- Registration Number
- NCT03723083
- Locations
- 🇺🇸
Celgene, Summit, New Jersey, United States
Expanded Access for AG-221
- Conditions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2019-10-24
- Lead Sponsor
- Celgene
- Registration Number
- NCT03723057
- Locations
- 🇺🇸
Celgene, Summit, New Jersey, United States
Expanded Access for CC-4047
- Conditions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Celgene
- Registration Number
- NCT03723096
- Locations
- 🇺🇸
Celgene, Summit, New Jersey, United States
Expanded Access for CC-486
- Conditions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Celgene
- Registration Number
- NCT03723135
- Locations
- 🇺🇸
Celgene, Summit, New Jersey, United States
Individual Patient Compassionate Use of Fedratinib
- Conditions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Celgene
- Registration Number
- NCT03723148
- Locations
- 🇺🇸
Celgene, Summit, New Jersey, United States
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT03720366
- Locations
- 🇰🇷
Local Institution - 201, Seoul, Korea, Republic of
🇦🇺Local Institution - 101, Melbourne, Australia
🇰🇷Local Institution - 203, Seoul, Korea, Republic of
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 93
- Registration Number
- NCT03703375
- Locations
- 🇯🇵
Local Institution - 41422, Hidaka, Saitama-Pref, Japan
🇯🇵Local Institution - 41222, Sendai, Japan
🇯🇵Local Institution - 41722, Osakasayama, Osaka, Japan
Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response
- Conditions
- Interventions
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 92
- Registration Number
- NCT03694119
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
- Conditions
- Interventions
- First Posted Date
- 2018-09-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 363
- Registration Number
- NCT03682536
- Locations
- 🇺🇸
Local Institution - 114, Salt Lake City, Utah, United States
🇺🇸Local Institution - 107, Berkeley, California, United States
🇺🇸Local Institution - 115, San Diego, California, United States